UK markets closed

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.8700-0.4300 (-33.08%)
At close: 05:01PM BST

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln 4133
Switzerland
41 61 906 89 50
https://www.santhera.com

Sector(s)
Industry
Full-time employees39

Key executives

NameTitlePayExercisedYear born
Dr. Thomas Meier Ph.D.Founder & Chairman61.25kN/A1962
Mr. Dario EklundChief Exec. Officer715.4kN/A1968
Mr. Andrew P. Smith CGMA, FCMAChief Financial OfficerN/AN/A1963
Mr. Rudolf Hausmann Ph.D.Head of Technical Devel. & OperationsN/AN/AN/A
Ms. Eva KaliasHead of Investor Relations & CommunicationsN/AN/AN/A
Mr. Oliver StrubExec. VP, Gen. Counsel & Sec.N/AN/A1963
Mr. Neville Kodkani M.D.Head of Global Marketing & Partner ManagementN/AN/AN/A
Ms. Sarah Holmes-KlotzHead of People & CultureN/AN/AN/A
Mr. Günther Metz Ph.D.Head of Bus. Devel. & Exec. VPN/AN/A1958
Mr. Shabir Hasham M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Corporate governance

Santhera Pharmaceuticals Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.